X4 Pharmaceuticals (XFOR) Total Non-Current Liabilities (2017 - 2025)

X4 Pharmaceuticals has reported Total Non-Current Liabilities for 9 years, with the latest figure at $103.6 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 6.24% year-over-year to $103.6 million; the trailing twelve-month figure through Dec 2025 stood at $103.6 million (down 6.24% YoY), and the FY2025 full-year result was $103.6 million, down 6.24% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $103.6 million, up from $101.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $117.3 million in Q3 2024, with the low at $49.3 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $79.5 million across 5 years, with a median of $81.1 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 106.17% — and 2025, when it retreated 13.93%.
• X4 Pharmaceuticals' Total Non-Current Liabilities stood at $52.8 million in 2021, then grew by 10.67% to $58.4 million in 2022, then soared by 37.82% to $80.5 million in 2023, then surged by 37.36% to $110.5 million in 2024, then dropped by 6.24% to $103.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $103.6 million (Q4 2025), $101.0 million (Q3 2025), and $100.9 million (Q2 2025), per Business Quant data.